A patient classified as HCV-1a positive by both LiPA Siemens 2.0 and Abbott RealTime HCV-Genotype II, was instead infected with HCV-1g, as determined by phylogenetic-analysis of NS3-sequences. HCV-1g NS3-sequences to date available naturally harbor the resistance-substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3-positions within boceprevir-binding site, as determined by structural modeling. HCV-1g NS3-sequences show some similarities to HCV-4, poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir-treatment. Baseline genotypic-resistance testing may provide critical information for the management of first-generation protease-inhibitors based regimens, including both HCV genotype/subtype and natural resistance.
Cento, V., Landonio, S., De Luca, F., Di Maio, V., Micheli, V., Mirabelli, C., et al. (2013). A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy. ANTIVIRAL THERAPY [10.3851/IMP2529].
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy
PERNO, CARLO FEDERICO;CECCHERINI SILBERSTEIN, FRANCESCA
2013-02-15
Abstract
A patient classified as HCV-1a positive by both LiPA Siemens 2.0 and Abbott RealTime HCV-Genotype II, was instead infected with HCV-1g, as determined by phylogenetic-analysis of NS3-sequences. HCV-1g NS3-sequences to date available naturally harbor the resistance-substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3-positions within boceprevir-binding site, as determined by structural modeling. HCV-1g NS3-sequences show some similarities to HCV-4, poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir-treatment. Baseline genotypic-resistance testing may provide critical information for the management of first-generation protease-inhibitors based regimens, including both HCV genotype/subtype and natural resistance.Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
